Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer
Shinjiro Sakamoto(Kurume University), Tetsuro Sasada(Kanagawa Prefectural Hospital Organization), Shigeki Shichijo, Noboru Hattori(Hiroshima University), Masanori Noguchi(Kurume University), Koichi Yoshiyama(Kurume University), Shinzo Takamori(Kurume University), Yasuhiro Terazaki(Kurume University), Satoko Matsueda(Kurume University), Shunichi Sugawara(Sendai Kousei Hospital), Teppei Yamada(Harvard University), Kyogo Itoh(Kurume University), Nobuoki Kohno(Hiroshima University), Akira Yamada(Fujita Health University)
Cited by 15
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695